2,4-双(三氟甲基)苯甲酰氯 | 53130-43-1

• 物质功能分类: 化学试剂 - 有机试剂 - 酰卤
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2,4-双(三氟甲基)苯甲酰氯
• 中文别名: 2,4-双(三氟甲基)苯酰氯
• 英文名称: 2,4-bis(trifluoromethyl)benzoyl chloride
• CAS: 53130-43-1
• 化学式: C₉H₃ClF₆O
• mdl: MFCD00061227
• 分子量: 276.566
• InChiKey: TZXHEDOCQVTEPT-UHFFFAOYSA-N

物化性质

• 沸点：
  191-193°C
• 密度：
  1.512
• 闪点：
  191-193°C
• 稳定性/保质期：

  如果按照规格正确使用和储存，则不会发生分解，也没有已知的危险反应。

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  7

安全信息

• 危险等级：
  8
• 危险品标志：
  C
• 安全说明：
  S23,S26,S36/37/39,S45
• 危险类别码：
  R34
• 海关编码：
  2916399090
• 包装等级：
  II
• 危险类别：
  8
• WGK Germany：
  3
• 危险品运输编号：
  3265

反应信息

• 作为反应物：
  描述：

  2,4-双(三氟甲基)苯甲酰氯 在 正丁基锂 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 43.0h， 生成 benzo[d]thiazol-2-yl(2,4-bis(trifluoromethyl)phenyl)methanone
  参考文献：
  名称：

  Development of AC265347‐Inspired Calcium‐Sensing Receptor Ago‐Positive Allosteric Modulators

  摘要：

  AbstractThe calcium‐sensing receptor (CaSR) is a clinical target in the treatment of hyperparathyroidism and related diseases. However, clinical use of approved CaSR‐targeting drugs such as cinacalcet is limited due to adverse side effects including hypocalcaemia, nausea and vomiting, and in some instances, a lack of efficacy. The CaSR agonist and positive allosteric modulator (ago‐PAM), AC265347, is chemically distinct from clinically‐approved CaSR PAMs. AC265347 potently suppressed parathyroid hormone (PTH) release in rats with a lower propensity to cause hypocalcaemia compared to cinacalcet and may therefore offer benefits over current CaSR PAMs. Here we report a structure activity relationship (SAR) study seeking to optimise AC265347 as a drug candidate and disclose the discovery of AC265347‐like compounds with diverse pharmacology and improved physicochemical and drug‐like properties.

  DOI：

  10.1002/cmdc.202100368
• 作为产物：
  描述：

  2,4-双(三氟甲基)苯甲酸 在 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.5h， 生成 2,4-双(三氟甲基)苯甲酰氯
  参考文献：
  名称：

  Development of AC265347‐Inspired Calcium‐Sensing Receptor Ago‐Positive Allosteric Modulators

  摘要：

  AbstractThe calcium‐sensing receptor (CaSR) is a clinical target in the treatment of hyperparathyroidism and related diseases. However, clinical use of approved CaSR‐targeting drugs such as cinacalcet is limited due to adverse side effects including hypocalcaemia, nausea and vomiting, and in some instances, a lack of efficacy. The CaSR agonist and positive allosteric modulator (ago‐PAM), AC265347, is chemically distinct from clinically‐approved CaSR PAMs. AC265347 potently suppressed parathyroid hormone (PTH) release in rats with a lower propensity to cause hypocalcaemia compared to cinacalcet and may therefore offer benefits over current CaSR PAMs. Here we report a structure activity relationship (SAR) study seeking to optimise AC265347 as a drug candidate and disclose the discovery of AC265347‐like compounds with diverse pharmacology and improved physicochemical and drug‐like properties.

  DOI：

  10.1002/cmdc.202100368

文献信息

• Catalytic Enantioselective Synthesis of Lactams through Formal [4+2] Cycloaddition of Imines with Homophthalic Anhydride
  作者：Claire L. Jarvis、Jennifer S. Hirschi、Mathew J. Vetticatt、Daniel Seidel

  DOI：10.1002/anie.201612148

  日期：2017.3.1

  An amide‐thiourea compound, operating through a novel ion pairing mechanism, is an efficient organocatalyst for the asymmetric reaction of homophthalic anhydride with imines. N‐aryl and N‐alkyl imines readily undergo formal [4+2] cycloaddition to provide lactams with high levels of enantio‐ and diastereoselectivity. The nature of the key chiral ion pair intermediate was elucidated by DFT calculations

  通过新颖的离子对机理运行的酰胺硫脲化合物是一种高效的有机催化剂，用于高纯邻苯二甲酸酐与亚胺的不对称反应。N-芳基和N-烷基亚胺易于进行正式的[4 + 2]环加成反应，从而为内酰胺提供高水平的对映体和非对映体选择性。关键的手性离子对中间体的性质通过DFT计算得以阐明。
• Scavenger assisted combinatorial process for preparing libraries of amides, carbamates and sulfonamides
  申请人：ELI LILLY AND COMPANY

  公开号：EP0825164A2

  公开（公告）日：1998-02-25

  This invention relates to a novel solution phase process for the preparation of amide, carbamate, and sulfonamide combinatorial libraries. These libraries have utility for drug discovery and are used to form wellplate components of novel assay kits.

  这项发明涉及一种用于制备酰胺、碳酸酯和磺酰胺组合库的新型溶液相过程。这些库在药物发现中具有实用价值，并用于形成新型检测套件的微孔板组件。
• [EN] NEW AMINOACID COMPOUNDS FOR TREATING TUMOURS AND AUTOIMMUNE DISEASES<br/>[FR] NOUVEAUX COMPOSÉS D'ACIDE AMINÉ SERVANT À TRAITER LES TUMEURS ET LES MALADIES AUTO-IMMUNES
  申请人：ARKE ORGANICS S R L

  公开号：WO2013029648A1

  公开（公告）日：2013-03-07

  A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein: - R' is H or F or trifluoromethyl; - R'' is OH or O-alkyl; - R''' is H or F or trifluoromethyl or phenyl or pyridyl; - R'''' is methylene or acylsulfanyl or phenacylsulfanyl or aryloylsulfanyl or thien-2-ylsulfanyl, thiazol-2-ylsulfanyl; - n is 0 or 1, as well as pharmaceutical composition containing at least of such compounds for treating neoplasms, including tumours and carcinomas, and autoimmune diseases, including rheumatoid arthritis.

  一种具有式（I）的化合物或其药学上可接受的盐或溶剂，其中：- R'为H或F或三氟甲基；- R''为OH或O-烷基；- R'''为H或F或三氟甲基或苯基或吡啶基；- R''''为亚甲基或酰基硫醚基或苯乙酰硫醚基或芳基酰硫醚基或噻吩-2-基硫醚基，噻唑-2-基硫醚基；- n为0或1，以及包含至少这类化合物的药物组合物，用于治疗肿瘤，包括肿瘤和癌症，以及自身免疫性疾病，包括类风湿性关节炎。
• Synthesis of different thio-scaffolds bearing sulfonamide with subnanomolar carbonic anhydrase II and IX inhibitory properties and X-ray investigations for their inhibitory mechanism
  作者：Andrea Angeli、Damiano Tanini、Antonella Capperucci、Gianni Malevolti、Francesca Turco、Marta Ferraroni、Claudiu T. Supuran

  DOI：10.1016/j.bioorg.2018.09.028

  日期：2018.12

  inhibitors of Carbonic Anhydrases (CAIs). The structure-activity relationship analysis identified thioether derivatives, here reported, as a potent and selective CAIs against hCA II and hCA IX. High resolution X-ray structure of inhibitor bound hCA II revealed extensive interactions with the hydrophobic pocket of active site and provided molecular insight into the binding properties of these new inhibitors

  设计，合成和合成了几种具有不同硫代骨架的新分子，并对它们进行了碳酸酐酶（CAIs）抑制剂的生物学评估。结构-活性关系分析确定了硫醚衍生物（本文报道）是针对hCA II和hCA IX的有效和选择性的CAI。抑制剂结合的hCA II的高分辨率X射线结构揭示了与活性位点疏水口袋的广泛相互作用，并提供了对这些新抑制剂结合特性的分子洞察力。
• [EN] BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS<br/>[FR] PETITES MOLÉCULES CONTENANT DU BORE ET UTILISABLES EN TANT QU'AGENTS ANTIPROTOZOAIRES
  申请人：ANACOR PHARMACEUTICALS INC

  公开号：WO2011019618A1

  公开（公告）日：2011-02-17

  This invention provides, among other things, novel compounds useful for treating protozoal infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent. The compounds have the following formula: wherein X is selected from the group consisting of substituted phenyl, substituted or unsubstituted heteroaryl and unsubstituted cycloalkyl; R3a is selected from the group consisting of H1 unsubstituted C1 or C2 or C3 or C4 or C5 or C6 alkyl and unsubstituted C3 or C4 or C5 or C6 cycloalkyl; R3b is selected from the group consisting of H, unsubstituted C1 or C2 or C3 or C4 or C5 or C6 alkyl and unsubstituted C3 or C4 or C5 or C6 cycloalkyl; with the proviso that R3a and R3b, along with the atom to which they are attached, are optionally joined to form a 3 or 4 or 5 or 6 membered ring, with the proviso that R3a and R3b cannot both be H, or a salt thereof.

  这项发明提供了用于治疗原虫感染的新化合物，包含这些化合物的药物组合物，以及这些化合物与至少一种额外治疗有效剂的组合物。这些化合物具有以下结构式：其中X选自取代苯基、取代或未取代杂环芳基和未取代环烷基的组；R3a选自H1未取代的C1或C2或C3或C4或C5或C6烷基和未取代的C3或C4或C5或C6环烷基的组；R3b选自H、未取代的C1或C2或C3或C4或C5或C6烷基和未取代的C3或C4或C5或C6环烷基的组；但R3a和R3b，以及它们连接的原子，可选地结合形成3、4、5或6元环，但R3a和R3b不能同时为H，或其盐。